Geode Capital Management
ORIC icon

Geode Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Geode Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6M Buy
2,090,089
+251,288
+14% +$2.28M ﹤0.01% 2078
2026
Q1 		$23.3M Buy
1,838,801
+88,107
+5% +$1M ﹤0.01% 1920
2025
Q4 		$14.3M Buy
1,750,694
+119,950
+7% +$1.38M ﹤0.01% 2201
2025
Q3 		$19.6M Buy
1,630,744
+522,284
+47% +$5.49M ﹤0.01% 2012
2025
Q2 		$11.3M Sell
1,108,460
-197,531
-15% -$1.33M ﹤0.01% 2282
2025
Q1 		$7.29M Buy
1,305,991
+27,278
+2% +$239K ﹤0.01% 2473
2024
Q4 		$10.3M Buy
1,278,713
+5,200
+0.4% +$47.7K ﹤0.01% 2351
2024
Q3 		$13.1M Buy
1,273,513
+50,821
+4% +$502K ﹤0.01% 2220
2024
Q2 		$8.65M Buy
1,222,692
+311,059
+34% +$2.78M ﹤0.01% 2412
2024
Q1 		$12.5M Buy
911,633
+36,742
+4% +$436K ﹤0.01% 2190
2023
Q4 		$8.05M Buy
874,891
+54,444
+7% +$394K ﹤0.01% 2454
2023
Q3 		$4.96M Buy
820,447
+91,065
+12% +$746K ﹤0.01% 2646
2023
Q2 		$5.66M Buy
729,382
+421,960
+137% +$2.4M ﹤0.01% 2613
2023
Q1 		$1.75M Buy
307,422
+23,711
+8% +$124K ﹤0.01% 3091
2022
Q4 		$1.67M Sell
283,711
-597
-0.2% -$2.02K ﹤0.01% 3124
2022
Q3 		$909K Sell
284,308
-40,065
-12% -$160K ﹤0.01% 3435
2022
Q2 		$1.45M Sell
324,373
-254,449
-44% -$1.02M ﹤0.01% 3244
2022
Q1 		$3.09M Sell
578,822
-37,050
-6% -$334K ﹤0.01% 3041
2021
Q4 		$9.05M Sell
615,872
-35,352
-5% -$551K ﹤0.01% 2516
2021
Q3 		$13.6M Buy
651,224
+243,343
+60% +$4.93M ﹤0.01% 2240
2021
Q2 		$7.21M Buy
407,881
+71,418
+21% +$1.57M ﹤0.01% 2693
2021
Q1 		$8.24M Buy
336,463
+21,963
+7% +$694K ﹤0.01% 2492
2020
Q4 		$10.6M Buy
314,500
+174,895
+125% +$5.02M ﹤0.01% 2133
2020
Q3 		$3.49M Buy
139,605
+1,479
+1% +$35.2K ﹤0.01% 2590
2020
Q2 		$4.66M Buy
+138,126
New +$4.41M ﹤0.01% 2378

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's ORIC Position: Q2 2026 in Review

Geode Capital Management increased its Oric Pharmaceuticals (ORIC) stake by 14% in Q2 2026, buying an estimated $2.28M and bringing the position to 2,090,089 shares worth $22.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Geode Capital Management first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $23.3M in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Geode Capital Management held 2,090,089 shares of Oric Pharmaceuticals worth $22.6M as of Q2 2026.
  • Geode Capital Management bought 251,288 Oric Pharmaceuticals shares in Q2 2026, an estimated $2.28M.
  • Oric Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2078 holding.
  • Geode Capital Management first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Geode Capital Management's Oric Pharmaceuticals position peaked at $23.3M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.